
Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Hot of the press: new issue of BIOTECH Insight
The current issue of the BIOTECH Insight Newsletter, launched in December 2021 by Deutsche Börse with support of BIOCOM AG, addresses hot topics in...

Mosaic Therapeutics closes $28m series A financing
Oncology specialist Mosaic Therapeutics Ltd will use a $28m financing to push its preclinical pipeline of targeted oncology therapies for...